News in brief

BioDuro teams up with API developer Porton

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/daizuoxin)
(Image: iStock/daizuoxin)

Related tags: Pharmacology

The San Diego-CA-based contract research, development, and manufacturing organization (CDMO), BioDuro, has announced a cooperation agreement with Porton Pharma Solutions.

Previously Porton Fine Chemicals, the newly renamed company operates three process technology centers and three manufacturing sites in China.

Under the cooperation agreement, BioDuro will promote and market Porton's custom active pharmaceutical ingredient (API) and cGMP manufacturing services.

In turn, Porton will incorporate BioDuro's technologies and resources in drug discovery, as well as its formulations development and clinical trial materials (CTMs) manufacturing capabilities, into its solutions suite.

Cyrus K. Mirsaidi, BioDuro president and CEO, said the partnership expands the company’s reach to provide fully integrated API and drug product development and manufacturing solutions.

"Porton's global footprint and proven track record with many of the world's leading pharmaceutical companies will provide substantiated channels for timely and reliable delivery of high value therapeutics, using innovative and cost effective manufacturing routes, backed by high-quality assets in Asia and North America​," he said in a press release.

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars